(Q43142546)

14 November 2017

title

Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study (English)

1 reference

14 November 2017

José Zamorano

1

1 reference

14 November 2017

Serap Erdine

2

1 reference

14 November 2017

Abel Pavia Lopez

3

1 reference

14 November 2017

Jae-Hyung Kim

4

1 reference

14 November 2017

Ayman Al Khadra

5

1 reference

14 November 2017

Mogens Westergaard

6

1 reference

14 November 2017

Santosh Sutradhar

7

1 reference

14 November 2017

Carla Yunis

8

1 reference

14 November 2017

CRUCIAL Investigators

9

1 reference

14 November 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

14 November 2017

published in

Postgraduate Medicine

1 reference

14 November 2017

volume

122

1 reference

14 November 2017

issue

2

1 reference

14 November 2017

page(s)

7-15

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Barriers to optimal hypertension control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Contamination in trials: is cluster randomisation the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

Probability of stroke: a risk profile from the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.03.2117

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.03.2117

1 reference

14 November 2017

1 reference